scispace - formally typeset
C

Carol Durno

Researcher at University of Toronto

Publications -  58
Citations -  3450

Carol Durno is an academic researcher from University of Toronto. The author has contributed to research in topics: DNA mismatch repair & Cancer. The author has an hindex of 24, co-authored 51 publications receiving 2685 citations. Previous affiliations of Carol Durno include Hospital for Sick Children & Mount Sinai Hospital.

Papers
More filters
Journal ArticleDOI

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

TL;DR: This report of initial and durable responses of recurrent GBM to immune checkpoint inhibition may have implications for GBM in general and other hypermutant cancers arising from primary (genetic predisposition) or secondary MMRD.
Journal ArticleDOI

Comprehensive Analysis of Hypermutation in Human Cancer

Brittany Campbell, +63 more
- 16 Nov 2017 - 
TL;DR: An extensive assessment of mutation burden through sequencing analysis of >81,000 tumors from pediatric and adult patients, including tumors with hypermutation caused by chemotherapy, carcinogens, or germline alterations, uncovered new driver mutations in the replication-repair-associated DNA polymerases and a distinct impact of microsatellite instability and replication repair deficiency on the scale of mutation load.
Journal ArticleDOI

Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers.

TL;DR: A new mechanism of cancer progression is suggested in which mutations develop in a rapid burst after ablation of replication repair, which implies a threshold compatible with cancer-cell survival.
Journal ArticleDOI

Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis.

TL;DR: Patients with CF with pancreatic sufficiency carry at least one mild mutant allele and are at a significant risk of developing pancreatitis, which is associated with an otherwise mild CF phenotype.